Literature DB >> 24383825

Wnt signaling in rheumatoid synoviocyte activation.

M Sen1, D A Carson.   

Abstract

Abstract Rheumatoid arthritis (RA) is a joint-specific disease with complex pathogenesis. It is characterized by synovial inflammation, cartilage loss, and joint destruction. The reasons why joint damage recurs when therapy is discontinued are not clearly understood. Several lines of evidence suggest that cartilage damage is promoted by the transformed and invasive fibroblast-like synoviocytes (FLS) of the rheumatoid joint. It has been demonstrated in several systems that aberrant wnt-mediated signaling causes blockade of cartilage differentiation and malformation of joints. In this review, we have discussed the importance of wnt-frizzled-mediated signaling in the autonomous activation of FLS in patients with RA. Anti-wnt/anti-frizzled antibodies, frizzled receptor antagonists, or small molecule inhibitors of wnt-frizzled signaling might be useful for therapeutic interventions in RA.

Entities:  

Year:  2002        PMID: 24383825     DOI: 10.3109/s101650200001

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  4 in total

1.  Overexpression of Aquaporin 1 in Synovium Aggravates Rat Collagen-Induced Arthritis Through Regulating β-Catenin Signaling: An in vivo and in vitro Study.

Authors:  Yu-Rong Mu; Meng-Yuan Zhou; Li Cai; Ming-Ming Liu; Rong Li
Journal:  J Inflamm Res       Date:  2020-10-08

Review 2.  Wnt5a: a player in the pathogenesis of atherosclerosis and other inflammatory disorders.

Authors:  Pooja M Bhatt; Ramiro Malgor
Journal:  Atherosclerosis       Date:  2014-09-03       Impact factor: 5.162

Review 3.  The Regulation of Bone Metabolism and Disorders by Wnt Signaling.

Authors:  Kazuhiro Maeda; Yasuhiro Kobayashi; Masanori Koide; Shunsuke Uehara; Masanori Okamoto; Akihiro Ishihara; Tomohiro Kayama; Mitsuru Saito; Keishi Marumo
Journal:  Int J Mol Sci       Date:  2019-11-06       Impact factor: 5.923

Review 4.  The Role of Sclerostin in Bone Diseases.

Authors:  Elias S Vasiliadis; Dimitrios-Stergios Evangelopoulos; Angelos Kaspiris; Ioannis S Benetos; Christos Vlachos; Spyros G Pneumaticos
Journal:  J Clin Med       Date:  2022-02-02       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.